Burning Rock Biotech Ltd

Burning Rock Biotech Ltd reported a significant decline in its first quarter 2026 financial results. Total revenues decreased by 18.9% year-over-year to RMB107.9 million ($15.6 million), leading to a wider net loss of RMB17.5 million ($2.5 million) compared to the prior year. The revenue decline was observed across all business segments, primarily due to a decrease in test volumes and one-off issues affecting in-hospital revenue. The company also highlighted recent business updates, including presentations of multiple study results at the 2026 AACR and Journal for ImmunoTherapy of Cancer.

Burning Rock Biotech Ltd announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission on April 28, 2026. The report is available for public viewing on both the SEC's website and the Company's investor relations website. Shareholders and ADS holders can request a hard copy of the Form 20-F, which includes the audited consolidated financial statements, free of charge.